Furiex Makes Inroads In Tough-To-Treat IBS-d With Positive Phase III Eluxadoline Data
This article was originally published in The Pink Sheet Daily
Eluxadoline met endpoints in two Phase III studies, positioning the drug for submission in a sparsely served therapeutic area, with only one FDA-approved drug and millions of patients in the U.S. and EU. Mild pancreatitis was reported in a handful of patients, but is manageable, company says.
You may also be interested in...
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.
Acquisitions boosted Forest’s 2014 sales, and the company isn’t slowing down its acquisition strategy even though it is working toward a merger with Actavis.
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.